Hilltop BioSciences to Advance Animal Care by Unveiling Three New Regenerative Therapies

Hilltop BioSciences will advance its suite of regenerative therapies by introducing three new formulations, Regenaflex-K9, Regenaflex-M Biofilm, and PureOptic, for veterinarian applications.

"Regenaflex has significant potential in the companion animal marketplace," says Hilltop Bio Chief Executive Officer Amanda Drobnis. "We look forward to introducing our innovative regenerative products at VMX."

Hilltop BioSciences, one of the leading biotech companies pioneering the development of innovative regenerative therapies, aims to unveil a series of new formulations at VMX in Orlando.

One of the established players in the equine arena, Regenaflex, provides solutions that involve sending intracellular signals to the affected area to stimulate cell-to-cell communication and promote healing soft tissue. This cascade includes cytokines, microRNA, growth factors, and exosomes.

It takes less than a minute to reconstitute Regenaflex for immediate use. Compared to biologics such as platelet-rich plasma (PRP), stem cells, and conditioned serum products, Hilltop Bios products have long-term room-temperature storage and consistent compositions in every dose. They are formulated to target specific indications without special equipment or time-consuming processing.

Its three formulations are Regenaflex-K9, Regenaflex-M Biofilm, and PureOptic.

Veterinary practitioners can use Regenaflex-K9 as a regenerative soft tissue treatment. Regenaflex-M Biofilm promotes tissue healing by inhibiting inflammation, infection, and adhesion. The Biofilm minimizes scar tissue formation after abdominal or orthopedic surgery without causing postoperative adhesions. This formulation can also prevent postoperative sutures after intestinal anastomosis or cystostomy. PureOptic eye drops provide the same powerful healing cargo as Hilltop's other products, and literature indicates that they can help normalize damaged tissue caused by eye injuries or diseases.

According to Heather Sherman, DVM, "This was kind of a slam dunk case. There was no negative reaction to [Regenaflex], and the leg responded better than I would've expected given the animal's age and the absence of any adjunctive therapies."